-
Adagene Achieves CAR-T Collaboration Milestone
contractpharma
January 13, 2021
Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.
-
Mayo Clinic researchers identify new strategies that may improve CAR-T cell therapy
firstwordpharma
December 05, 2018
Sterner says some patients undergoing CAR-T cell therapy get sick during treatment and require a stay in an ICU. She also notes that deaths related to the side effects of CAR-T cell therapy have been reported. Sterner and her colleagues developed a strate
-
Mayo Clinic researchers identify new strategies that may improve CAR-T cell therapy
firstwordpharma
December 05, 2018
Sterner says some patients undergoing CAR-T cell therapy get sick during treatment and require a stay in an ICU. She also notes that deaths related to the side effects of CAR-T cell therapy have been reported. Sterner and her colleagues developed a strate
-
FDA puts clinical hold on Cellectis' CAR-T cell therapies
biospectrumasia
September 19, 2017
Cellectis said it is working with clinical trial investigators and the FDA to resume the trials with an amended trial protocol that includes a lower dose of UCART123.
-
Novartis granted first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019)
Novartis
August 31, 2017
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice.
-
Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation for Treatment of Ad
drugs.com
April 19, 2017
Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019...
-
Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform
firstwordpharma
January 23, 2017
Orgenesis Inc. (OTCQB: ORGS) has signed a master service agreement with Servier for the development of a manufacturing platform for allogeneic cell therapies. Under the master service agreement, MaSTherCell is developing a CAR-T cell therapy manufacturing